Clinical Insights - Feb 3, 2026

Recent pediatric consensus guidance aligns neonatal and pediatric vancomycin monitoring with adult practice by endorsing area-under-the-curve(AUC)-based therapeutic drug monitoring rather than trough-based monitoring. The recommended pharmacodynamic target is an AUC/MIC of 400-600 mg·h/L, assuming an MIC of 1 mg/L. This replaces historical trough targets which are poor surrogates for total exposure in children, with reported correlations between trough and AUC as low as r² = 0.082.

Empiric dosing recommendations have also evolved. For serious infections, initial dosing has increased from 60 mg/kg/day to 60-80 mg/kg/day in children with normal renal function. A 20 mg/kg loading dose is now recommended for pediatric patients with obesity to address a larger volume of distribution and delayed attainment of target exposure. Monitoring is advised within the first 24-48 hours of therapy, as Bayesian methods that can estimate AUC early in treatment.

Outcome data supporting this shift are largely indirect. Pediatric observational studies and meta-analyses associate AUC-guided monitoring with lower rates of vancomycin-associated nephrotoxicity compared with trough-based strategies, with an odds ratio near 0.53. Pediatric analyses suggest nephrotoxicity risk rises at AUC thresholds below the traditional 600 mg·h/L cutoff, beginning between 537 and 583 mg·h/L, reinforcing the need to avoid excessive exposure. Implementation remains uneven due to the need for Bayesian software, specialized expertise, and limited validation of pharmacokinetic models in neonates and in children receiving extracorporeal support or renal replacement therapy. In addition, while MRSA targets are relatively well-defined, optimal AUC/MIC ratios for common neonatal pathogens such as coagulase-negative Staphylococcus remain uncertain, warranting caution when extrapolating targets across organisms.¹

Caffeine therapy for apnea of prematurity is typically discontinued around 34 weeks postmenstrual age as the respiratory drive begins maturing and the lungs start producing surfactant. Persistent apnea beyond this point should prompt investigating for other causes of apnea rather than reflexive continuation of caffeine.

A structured bedside approach can help identify secondary contributors. The “HANDS” framework highlights key categories to reassess: hypoglycemia, hypothermia, and electrolyte abnormalities; anemia; neurologic causes such as seizures or intraventricular hemorrhage; diseases including patent ductus arteriosus, chronic lung disease, sepsis, or pneumonia; and structural airway abnormalities such as laryngomalacia.

Caffeine therapy and the “HANDS” framework are reviewed in the video Pharmacology Fundamentals: Apnea of Prematurity.

On January 12, 2026, the AAP released an updated clinical report emphasizing that maternal or donor human milk should be regarded as a primary medical intervention for high-risk neonates, not solely as nutrition. The report calls for standardized institutional protocols to support lactation, donor milk access, and clinician accountability in neonatal units, noting that support for human milk is central to neonatal health and development.

For pediatric clinicians and pharmacists, this guidance has practical implications. Prioritizing human milk increases the need for careful review of maternal medication exposure during lactation, coordination with donor milk programs, and integration of lactation considerations into antimicrobial and supportive care decisions. The report reinforces evidence that human milk feeding reduces risks such as necrotizing enterocolitis and late-onset sepsis and positions lactation support as a patient safety and quality priority in neonatal care.²

If you received this via forwarding and would like to subscribe, you can sign up here: Subscribe to Pediatric Pearls

— Dr. Su